Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Effect of NNC 90-1170 on Hypoglycaemic Counterregulation During Stepwise Hypoglycaemic Clamp in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, 2-period Cross-over Trial

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01509742

Enrollment

Registered

2012-01-13

Start date

2001-04-30

Completion date

2001-11-30

Last updated

2024-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.

Interventions

DRUGliraglutide

Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

DRUGplacebo

Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 75 Years

Healthy volunteers

Inclusion criteria

age: minimum 30, maximum 75 years

Design outcomes

Primary

Measure	Time frame
Area under the Curve (AUC) glucagon	—

Secondary

Measure	Time frame
Glucose	—
Cortisol	—
Growth hormone	—
Insulin secretion	—
Noradrenaline	—
Adverse events	—
Adrenaline	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026